Leebeek FWG, Eikenboom JCJ (2016) Von willebrand’s disease. N Engl J Med 375:2067–2080. https://doi.org/10.1056/NEJMra1601561

Article  CAS  PubMed  Google Scholar 

Favaloro EJ, Pasalic L, Curnow J (2017) Monitoring therapy during treatment of von Willebrand disease. Semin Thromb Hemost 43(03):338–354

CAS  PubMed  Google Scholar 

Calabrò P, Gragnano F, Golia E, Grove EL (2018) Von Willebrand factor and venous thromboembolism: pathogenic link and therapeutic implications. Semin Thromb Hemost 44(03):249–260

Article  PubMed  Google Scholar 

Lenting PJ, Casari C, Christophe OD, Denis CV (2012) Von Willebrand factor: the old, the new and the unknown. J Thromb Haemost 10:2428–2437

Article  CAS  PubMed  Google Scholar 

Blennerhassett R, Curnow J, Pasalic L (2020) Immune-mediated thrombotic thrombocytopenic purpura: a narrative review of diagnosis and treatment in adults. Semin Thromb Hemost 46(03):289–301

Article  PubMed  Google Scholar 

South K, Lane DA (2018) ADAMTS-13 and von Willebrand factor: a dynamic duo. J Thromb Haemost 16:6–18. https://doi.org/10.1111/jth.13898

Article  CAS  PubMed  Google Scholar 

Li Z, Lin J, Sulchek T, Cruz MA, Wu J, Zhu C (2019) Domain-specific mechanical modulation of VWF–ADAMTS13 interaction. Mol Biol Cell 30:1920–1929. https://doi.org/10.1091/mbc.E19-01-0021

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scully M, Cataland SR, Peyvandi F, Coppo P, Knöl P, Kremer Hovinga JA et al (2019) Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 380:335–346. https://doi.org/10.1056/NEJMoa1806311

Article  CAS  PubMed  Google Scholar 

Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G (2019) An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy. Clin Kidney J 12(03):333–337

Article  PubMed  PubMed Central  Google Scholar 

Andersson HM, Siegerink B, Luken BM, Crawley JT, Algra A, Lane DA, Rosendaal FR (2012) High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood 119:1555–1560

Article  CAS  PubMed  Google Scholar 

Matsukawa M, Kaikitia K, Soejima K, Fuchigami S, Nakamura Y, Honda T, Tsujita K, nagayoshi Y, Kojima S, Shimomura H, Sugiyama S, Fujimoto K, Yoshimura M, Nakagaki T, Ogawa H (2007) Serial changes in von Willebrand factor-cleaving protease (ADAMTS 13) and prognosis after acute myocardial infarction. Am J Cardiol 100:758–763

Article  CAS  PubMed  Google Scholar 

Kaikita K, Soejima K, Matsukawa M, Nakagaki T, Ogawa H (2006) Reduced von Willebrand factor-cleaving protease (ADAMTS 13) activity in acute myocardial infarction. J Thromb Haemost 4:2490–2493

Article  CAS  PubMed  Google Scholar 

Crawley JT, Lane DA, Woodward M, Rumley A, Lowe GD (2008) Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal attack. J Thromb Haemost 6:583–588

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bongers TN, de Bruijne EL, Dippel DW, de Jong AJ, Deckers JW, Poldermans D, de Maat MP, Leebeck FW (2009) Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients. Atherosclerosis 207:250–254

Article  CAS  PubMed  Google Scholar 

Fujioka M, Nakano T, Hayakawa K, Irie K, Akitake Y, Sakamoto Y, Mishima K, Muroi C, Yonekawa Y, Banno F, Kokame K, Miyata T, Nishio K, Okuchi K, Iwasaki K, Fujiwara M, Siesjo BK (2012) ADAMTS 13 gene deletion enhances plasma high-mobility group box 1 elevation and neuroinflammation in brain ischemia-reperfusion injury. Neurol Sci 33:1107–1115

Article  PubMed  Google Scholar 

Zhao BQ, Chauhan AK, Canault M, Patten IS, Yang JJ, Dockal M, Scheifinger F, Wagner DD (2009) Von willebrand factor-cleaving protease ADAMTS 13 reduces ischemic brain injury in experimental stroke. Blood 114:3329–3334

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bongers TN, De Maat MP, van Goor ML, Bhagwanbali V, van Vliet HH, Gomez Garcia AB, Dippel DW, Leebeek FW (2006) High von willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS 13 inflammation, and genetic variability. Stroke 37:2672–2677

Article  CAS  PubMed  Google Scholar 

Mazetto BM, Orsi FL, Barnabé A, De Paula EV, Flores-Nascimento MC, Annichino-Bizzacchi JM (2012) Increased ADAMTS13 activity in patients with venous thromboembolism. Thromb Res 130:889–893

Article  CAS  PubMed  Google Scholar 

Pepin M, Kleinjan A, Hajage D, Buller HR, Di Nisio M, Kamphuisen PW, Salomon L, Veyradier A, Stepanian A, Mahe I (2016) ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer. J Thromb Haemost 14:306–315

Article  CAS  PubMed  Google Scholar 

Llobet D, Tirado I, Vilalta N, Vallvé C, Oliver A, Vázquez-Santiago M, Mateo J, Millón J, Fontcuberta J, Souto JC (2017) Low ADAMTS13 levels are associated with venous thrombosis risk in women. Thromb Res 157:38–40. https://doi.org/10.1016/j.thromres.2017.07.001

Article  CAS  PubMed  Google Scholar 

Obermeier HL, Riedl J, Ay C, Koder S, Quehenberger P, Bartsch R, Kaider A, Zielinski CC, Pabinger I (2019) The role of ADAMTS-13 and von Willebrand factor in cancer patients: results from the Vienna cancer and thrombosis study. Res Pract Thromb Haemost 3:503–514. https://doi.org/10.1002/rth2.12197

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pagliari MT, Boscarino M, Cairo A, Mancini I, Martinelli I, Bucciarelli P, Rossi F, Rosendaal FR, Peyvandi F (2021) ADAMTS13 activity, high VWF and FVIII levels in the pathogenesis of deep vein thrombosis. Thromb Res. https://doi.org/10.1016/j.thromres.2020.10.037

Article  PubMed  Google Scholar 

Edvardsen MS, Hansen ES, Ueland T, Aukrust P, Brækkan SK, Morelli VM, Hansen JB (2023) Impact of the von Willebrand factor-ADAMTS-13 axis on the risk of future venous thromboembolism. JThrombHaemost. https://doi.org/10.1016/j.jtha.2023.01.024

Article  Google Scholar 

Favaloro EJ, Henry BM, Lippi G (2021) Increased VWF and decreased ADAMTS-13 in COVID-19: creating a Milieu for (Micro)Thrombosis. Semin Thromb Hemost 47:400–418. https://doi.org/10.1055/s-0041-1727282

Article  CAS  PubMed  Google Scholar 

Vázquez-Santiago M, Vilalta N, Cuevas B, Murillo J, Llobet D, Macho R et al (2018) Short closure time values in PFA-100 are related to venous thrombotic risk. results from the RETROVE study. Thromb Res 169:57–63

Article  PubMed  Google Scholar 

Martinez C, Cohen AT, Bamber L, Rietbrock S (2014) Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer. Thromb Haemost 112:255–263

Article  CAS  PubMed  Google Scholar 

Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing GJ, Kyrle PA (2016) Subcommittees on control of anticoagulation, and predictive and diagnostic variables in thrombotic disease. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost 14:1480–1483

Article  CAS  PubMed  Google Scholar 

Yang J, Wu Z, Long Q, Huang J, Hong T, Liu W, Lin J (2020) Insights into immunothrombosis: the interplay among neutrophil extracellular trap, von Willebrand factor, and ADAMTS13. Front Immunol 11:610696. https://doi.org/10.3389/fimmu.2020.610696

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS et al (2004) Neutrophil extracellular traps kill bacteria. Science 303:1532–1535. https://doi.org/10.1126/science.1092385

Article  CAS  PubMed